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Abstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert
panellists met on 15 January 2014 to review current evidence on the management of hilar cholangio-
carcinoma in order to establish practice guidelines and to agree consensus statements. It was estab-
lished that the treatment of patients with hilar cholangiocarcinoma requires a coordinated,
multidisciplinary approach to optimize the chances for both durable survival and effective palliation. An
adequate diagnostic and staging work-up includes high-quality cross-sectional imaging; however,
pathologic confirmation is not required prior to resection or initiation of a liver transplant trimodal treat-
ment protocol. The ideal treatment for suitable patients with resectable hilar malignancy is resection of
the intra- and extrahepatic bile ducts, as well as resection of the involved ipsilateral liver. Preoperative
biliary drainage is best achieved with percutaneous transhepatic approaches and may be indicated for
patients with cholangitis, malnutrition or hepatic insufficiency. Portal vein embolization is a safe and
effective strategy for increasing the future liver remnant (FLR) and is particularly useful for patients with
an FLR of <30%. Selected patients with unresectable hilar cholangiocarcinoma should be evaluated
for a standard trimodal protocol incorporating external beam and endoluminal radiation therapy, sys-
temic chemotherapy and liver transplantation. Post-resection chemoradiation should be offered to
patients who show high-risk features on surgical pathology. Chemoradiation is also recommended for
patients with locally advanced, unresectable hilar cancers. For patients with locally recurrent or meta-
static hilar cholangiocarcinoma, first-line chemotherapy with gemcitabine and cisplatin is recom-
mended based on multiple Phase II trials and a large randomized controlled trial including a
heterogeneous population of patients with biliary cancers.
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Evaluation and staging of suspected hilar
cholangiocarcinoma
Epidemiology and clinical presentation
Hilar cholangiocarcinoma (Hilar CC) is a rare malignancy,
approximately 7000 cases of which are diagnosed per year in
North America. Its incidence has remained stable over the past
three decades. Among bile duct cancers, however, it is the most
common type. Known risk factors include primary sclerosing
cholangitis (PSC), liver fluke infestation (Clonorchis sinensis
and Opisthorchis viverrini) and hepatolithiasis, but most cases
are sporadic without an apparent inciting factor.1 Patients typi-
cally present with cachexia, fatigue and jaundice, often reflect-
ing locally advanced or metastatic disease. Approximately 90%
of patients present with biliary symptoms, including, most
commonly, painless jaundice. Up to 10% will have concomi-
tant cholangitis.2 The tendency toward presentation at an
advanced stage and the historical lack of effective systemic
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agents explain the resultant poor survival rates: most patients
succumb within a year of diagnosis.
Initial evaluation
The goals of preoperative evaluation are to rule out benign
causes of hilar obstruction, to identify patients with early-
stage disease who may benefit from surgical therapy, and
to provide palliative biliary drainage and systemic treatment
to those with advanced disease and preserved performance
status.
Pathologically, there are three subtypes of extrahepatic bile
duct adenocarcinoma, including the sclerosing (>70%), nodu-
lar (20%) and papillary (5–10%) subtypes.1,3 The vast majority
of hilar CC are mucinous adenocarcinomas with a nodular or
sclerosing growth pattern that involves the rich lymphatic
plexus around the bile ducts early in the course of disease.
Over time, hilar lesions can progress locally with the formation
of a mass that frequently involves critical hilar vascular struc-
tures. Less commonly, patients present with a papillary form
that tends to have an endobiliary growth pattern and a more
favourable prognosis.
Laboratory and imaging work-up
In the absence of cholangitis, the work-up of the jaundiced
patient typically starts with laboratory investigation and imag-
ing. Carbohydrate antigen (CA) 19-9 levels may not be accu-
rate in the setting of hyperbilirubinaemia, but may be relevant
later in the evaluation after biliary decompression. In addition,
10% of patients may be Lewis antigen non-producers and thus
will not secrete CA 19-9.4 An elevated immunoglobulin G4
(IgG4) level may suggest eosinophilic cholangiopathy (lympho-
plasmacytic cholangiopathy).5,6 Ultrasonography demonstrates
intrahepatic biliary dilatation with a decompressed distal bile
duct and gallbladder, isolating the obstruction to the common
hepatic duct and/or hilum. High-quality cross-sectional imag-
ing before bile duct instrumentation is the single most impor-
tant and accurate step in the diagnostic algorithm. Depending
on institutional expertise this may be accomplished with thin-
slice, high-resolution computed tomography (CT) or magnetic
resonance imaging/magnetic resonance cholangiopancreatogra-
phy (MRI/MRCP).7 The diagnostic and staging accuracy of
both modalities significantly diminish after biliary stent place-
ment as a result of decompression and imaging artefacts.
Conventional CT has a tumour detection rate of 60–69%
and accuracy in determining resectability of 44–80%.7 Based
on this, conventional CT has limited value in hilar CC and its
main purpose is to determine the extent of extrahepatic dis-
ease. By contrast, high-resolution CT has been shown to accu-
rately predict resectability in most hilar CC, which is beneficial
in avoiding non-therapeutic laparotomies.7 The preferred tech-
nique is by helical high-resolution CT with at least arterial and
portovenous phases with rapid intravenous contrast bolus
(5 ml/s for a total of 150 ml). The section thickness should be
2.5 mm reconstructed at 1.25 mm and the radiologic interpre-
tation should focus on the location and extent of biliary
involvement (Bismuth–Corlette classification), involvement of
the hepatic arteries, portal veins, peritoneum and adjacent
structures, and intrahepatic metastases.
The advantages of MRI with MRCP include a clearer delin-
eation of the intrahepatic extension of the tumour within the
bile ducts and higher diagnostic specificity as MRI is better
able to diagnose some non-malignant aetiologies of hilar
obstruction. The main disadvantage of MRI refers to its lack of
accuracy in determining vascular invasion and therefore resect-
ability. Other disadvantages of MRI are the complexity of the
multiple protocols, the requirement for a high level of patient
cooperation in terms of motion and breathing in order to
achieve optimal images, and lack of information regarding the
extent of extrahepatic disease, including regional adenopathy,
peritoneal metastases and distant metastases, although diffu-
sion-weighted imaging strengthens the performance of MRI in
these areas. When both are well performed, the accuracy of
MRI and CT in predicting resectability should exceed 75%.
Hilar cholangiocarcinomas tend not to be fludeoxyglucose
(FDG)-avid, with the result that positron emission tomography
(PET) has low sensitivity for the diagnosis of cholangiocarcino-
ma as the cause of a hilar biliary obstruction. For patients with
a confirmed diagnosis, sensitivity rises for the detection of
regional and distant disease, but rarely adds to the information
available from other staging modalities. Some studies suggest
that PET findings may change the treatment protocol in a
small subset of hilar CC patients, but rarely does this occur in
the absence of previous suspicious findings and/or an unex-
plained elevation in the CA 19-9 level.8,9
Endobiliary procedures
The most common presentation of hilar CC is jaundice. Many
patients will undergo biliary drainage during the preoperative
preparatory phase. In patients without suspicion for a benign
cause of hilar biliary obstruction (e.g. Mirizzi syndrome, eosin-
ophilic cholangiopathy, intrahepatic gallstones, liver flukes,
etc.), preoperative pathologic confirmation is not required
prior to resection or transplantation, although confirmation is
mandatory prior to chemotherapy or radiation in most
instances. Provided that neoadjuvant protocols are available,
patients with suspicious regional lymphadenopathy should be
considered for endoscopic ultrasound (EUS) or laparoscopic
fine needle aspiration (FNA) of any suspicious nodes. Percuta-
neous or laparoscopic biopsy of the primary tumour is not
recommended in patients who are candidates for liver trans-
plantation because of the high risk for disseminated disease fol-
lowing these procedures.10 In a trial incorporating neoadjuvant
chemoradiotherapy followed by liver transplantation, the small
number of patients who underwent a transperitoneal FNA con-
firming adenocarcinoma had an extremely high rate of perito-
neal seeding at the time of operative staging.
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During biliary stenting, brushings can be attempted to con-
firm diagnosis. Because of the fibrotic nature of these tumours,
endobiliary washing/brushing yields a definitively positive result
in approximately 40% of patients with hilar CC.11 Use of fluo-
rescent in situ hybridization (FISH) targeting pericentromeric
regions of chromosomes 3, 7 and 17 can significantly enhance
the sensitivity of brush biopsy. Trisomy and tetrasomy are inde-
terminate criteria for malignancy. Polysomy is diagnostic of
malignancy, with sensitivity of 50% and specificity of >95%. It
is notable that clinical evaluation without the use of FISH accu-
rately predicts the presence of malignancy among resected
patients approximately 90% of the time.12–14 When resection is
undertaken with a presumptive diagnosis of hilar CC, a benign
aetiology is identified in approximately 10% of cases.15,16
Staging and classification
Bismuth and Corlette described their criteria for categorizing
perihilar bile duct cancers in 1975.17 This initial classification
of carcinomas of the hilus described the extent to which the
common hepatic duct, duct confluence, and left and right
ducts were involved by tumour. The descriptions correlate with
the operations required for complete extirpation and establish-
ment of biliary continuity. Subsequent classification by Jarna-
gin et al.18 incorporated vascular involvement, resulting lobar
atrophy, and extension to secondary biliary radicles. This sys-
tem is a useful framework for defining the resectability of hilar
lesions but describes the characteristics of only the primary
hilar tumour. The Mayo Clinic classification system includes
additional factors such as the size and multifocality of the pri-
mary tumour, the nodal and extraregional metastatic burden,
and clinical features such as jaundice and performance status.19
Finally, the American Joint Commission on Cancer (AJCC)
Cancer Staging Manual includes a tumour–node–metastasis
(TNM) staging classification for perihilar bile ducts which is
primarily used in resected patients.20 The seventh edition of
the AJCC manual has recently been evaluated and allows for a
better overall prediction of survival because of a refined
T-stage with better stratification of prognosis for resected
patients.21
Consensus statements
• The minimum diagnostic and staging work-up in suspected
hilar CC includes CA 19-9 level and high-quality cross-sec-
tional imaging (preferably before biliary stenting) of the
chest, abdomen and pelvis.
• Pathologic confirmation is not required prior to proceeding
with attempted resection or initiation of a liver transplanta-
tion protocol, provided that benign aetiologies have been
excluded and a complete staging evaluation has been com-
pleted.
• Percutaneous or laparoscopic biopsy of the primary tumour
is not recommended in patients who may be candidates for
transplantation because there is a high incidence of dissemi-
nated disease following those procedures.
• Imaging by FDG-PET lacks the sensitivity and specificity
required in a routine staging tool for patients with hilar CC.
Surgical treatment of hilar CC
Definition of resectability
Resection of the involved intra- and extrahepatic bile ducts, as
well as the associated hepatic lobe and caudate lobe, is the
standard of care for suitable patients, although many patients
present with unresectable disease. Five-year survival rates
following resection generally range from 25% to 50%, with
regional metastasis limiting longterm survival.18,22–24 Survival
is highly correlated with resection margin status. Median
survival and 5-year survival among patients with a negative
margin (R0) resection range from 27 months to 58 months
and from 27% to 45%, respectively. Among patients with a
positive microscopic or gross margin, median survival and
5-year survival are markedly worse, ranging from 12 months
to 21 months and from 0% to 23%, respectively.18,25–29
The primary principle underpinning the criteria for unresecta-
bility is the requirement for biliary reconstruction options and
adequate hepatic parenchyma. Patients in whom the tumour
extends into the liver and without a target for restoring biliary
continuity are unresectable. Patients with evidence of hepatic
atrophy of the anticipated remnant lobe or sector will not have
adequate parenchyma for recovery. With these principles in
mind, any of the following criteria categorize a non-metastatic
hilar cancer as unresectable: (i) bilateral segmental ductal exten-
sion; (ii) unilateral atrophy with either contralateral segmental
ductal or vascular inflow involvement, and (iii) unilateral
segmental ductal extension with contralateral vascular inflow
involvement. The improved margin-negative resection rates and
survival associated with caudate lobectomy for patients with
Bismuth–Corlette type III and IV lesions have been demon-
strated in several retrospective series.30–32 Although some
authors have described acceptable outcomes in patients under-
going portal vein resection and reconstruction in the setting of
main portal vein involvement, these operations should be under-
taken by only the most experienced centres with the appropriate
hepatobiliary and vascular surgery expertise. Vascular resections
should not be performed routinely in hilar CC and the decision
to resect the portal vein should be determined intraoperatively
based on vascular extension.
At the time of operative exploration, 20–50% of patients
have been found to be unresectable based on previously pub-
lished series; however, the rate of resectability should continue
to diminish as the sensitivity of contemporary imaging contin-
ues to improve.18,23,33–36 A margin-negative resection is
achieved in 70–80% of patients submitted to resection in these
series. In summary, although the criteria for resectability
are well defined, complete preoperative assessment does not
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eliminate the risk for non-therapeutic laparotomy or incom-
plete surgical resection.
Perioperative preparation
In light of the significant risk for postoperative adverse events,
considerable attention has been dedicated to developing strate-
gies for improving the patient’s condition at the time of surgery.
Portal vein embolization (PVE) is used to increase the size of
the future liver remnant (FLR) and has been shown to be effec-
tive in inducing lobar hypertrophy with minimal risk.33,37,38 A
meta-analysis published in 2008 reviewed 37 publications
involving 1140 patients undergoing PVE in preparation for
major hepatectomy and found that the FLR increased by an
average of 8–27% with no mortality and with morbidity of
<3%.37 If the FLR after PVE is ≤20% or the degree of hypertro-
phy is ≤5%, liver resection should be considered high-risk and
may be contraindicated.38 Portal vein embolization of the
segment IV branch improves the hypertrophy of segments
II and III. Biliary drainage should be established before PVE in
the case of biliary dilatation of the FLR.38
A more widely debated subject concerns the use and route
of preoperative biliary decompression in the jaundiced patient,
with proponents citing improved liver function from the relief
of jaundice as the major benefit, which may decrease postoper-
ative liver insufficiency and death, whereas detractors cite
increased infection rates, seeding along the percutaneous cathe-
ter tract, delay in therapy, and lack of studies demonstrating
efficacy.34,39–41 There is clear consensus that preoperative bili-
ary decompression is indicated in patients with cholangitis,
patients undergoing preoperative anti-neoplastic therapy,
patients with hyperbilirubinaemia-induced malnutrition, hepa-
tic insufficiency or renal insufficiency, and patients undergoing
PVE. Although some authors have advocated no preoperative
biliary decompression in patients with adequate nutritional sta-
tus and no cholangitis, others, especially those from centres in
Asia, have advocated biliary drainage as mandatory, regardless
of bilirubin level, because of the association between cholangi-
tis and outcome.41Some centres recommend preoperative bili-
ary decompression to reach a preoperative total bilirubin level
of <2–3 mg/dl, whereas others will perform resection in
patients without biliary drainage provided cholangitis and
nutritional status are adequate.
When high-quality, contrast-enhanced, cross-sectional
imaging is obtained, and suspicion remains for bile duct
cancer, decompression of the bile duct may be indicated with
either percutaneous transhepatic cholangiography (PTC) or
endoscopic retrograde cholangiopancreatography (ERCP). In
addition to the reduction of both procedural risks and need
for re-intervention, PTC catheters can provide much better
delineation of the extent of endobiliary tumour spread within
the liver for resection planning.42–44 Furthermore, the technical
success rate measured in time from first attempt to a satisfactory
biliary level is higher with the endoscopic approach (61 days)
than with PTC (44 days). In addition, more than half of
patients who first have endoscopic biliary drainage will later
require PTC to achieve the required therapeutic effect.45 Like-
wise, complex lesions may not respond adequately to
endobiliary drainage and hence, particularly in patients who
may be candidates for resection, the care team should not hesi-
tate to establish durable biliary drainage with percutaneous
catheters. Advocates for endoscopic nasobiliary drainage iden-
tify improved durability of drainage and decreased cholangitis
compared with endobiliary stenting, although they do recog-
nize the decrease in patient comfort imposed by nasal drain-
age. These findings have led some to recommend endoscopic
nasobiliary drainage as the ideal preoperative drainage
method.46,47
Role of liver transplantation
Although liver transplantation alone was found to be a dismal
failure in patients with hilar CC,13 it has evolved to represent a
promising option in patients with unresectable lesions when it
is used in combination with neoadjuvant chemoradiotherapy.
Studies that have utilized rigorous patient selection have shown
excellent results, with 5-year recurrence-free survival rates of
65–70% in patients with unresectable tumours.48,49 The risks
for disease progression and recurrence have been identified,
and this multimodal therapy has been successfully applied at
many centres.
Diagnostic criteria include: (i) positive or strongly suspicious
intraluminal brush or biopsy; (ii) a radiographic malignant-
appearing stricture plus either CA 19-9 of >100 U/ml in the
absence of acute bacterial cholangitis or polysomy on FISH,
and (iii) a well-defined mass on cross-sectional imaging.
Patients with metastases, prior abdominal radiotherapy pre-
cluding additional therapy, a previous attempt at surgical
resection with violation of the tumour plane, or any medical
condition precluding transplantation were excluded. Vascular
encasement and stricture/mass extension along the duct is not
a contraindication, although a mass with a clear radial diame-
ter of >3 cm is generally excluded (a longitudinal extension
along the duct for >3 cm does not imply exclusion). Of note,
there is no requirement for pathologic confirmation of a tissue
diagnosis.
Neoadjuvant therapy includes external beam radiotherapy
(EBRT) administered to a total dose of 4500 cGy (in 30 frac-
tions of 150 cGy twice daily for 3 weeks) with a continuous
infusion of 5-fluorouracil (5-FU) given for the duration of
EBRT. An endoluminal brachytherapy boost is then delivered
through transcatheter iridium-192 seeds. The strategy for deliv-
ery has changed from the administration of 2000 cGy over
24 h using low-dose brachytherapy to, most recently, high-dose
brachytherapy of 1200–1600 cGy in two to four fractions. An
EBRT boost of 1500 cGy in 10 fractions twice daily for 1 week
is also acceptable. Patients remain on oral capecitabine at
2000 mg/m2 of body surface area (BSA) in two divided doses
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for 2 weeks in every 3-week period until transplantation. Oper-
ative exploration with routine biopsy of hepatic artery and
pericholedochal lymph nodes plus any suspicious lesion is per-
formed near the anticipated time of transplantation, and trans-
plantation may involve either a deceased or living donor
allograft.
The indications and rationale for liver transplantation differ
between patients with PSC and those with de novo hilar CC
outside the setting of PSC, non-alcoholic steatohepatitis
(NASH), or even occasionally hepatitis C viral infection.
Patients with PSC are characterized by multifocal intrahepatic
disease sites and extensive periductal fibrosis. The multifocality
of the ductal lesions frequently precludes resection as a defini-
tive option in patients with PSC. Outcomes following liver
transplantation alone for incidentally diagnosed cholangiocarci-
noma among patients with PSC are poor, with 3-year overall
survival of <40%.50 When combined with a pre-transplant reg-
imen of chemotherapy and radiation, 5-year survival from the
start of therapy ranges from 55% to 65% among patients with
cholangiocarcinoma arising in a background of PSC.51,52
In patients with unresectable de novo hilar CC, survival falls
short of that seen in patients with PSC. From the start of ther-
apy, 5-year patient survival ranges from 35% to 55% among
these de novo patients.48,49 For these unresectable patients, neo-
adjuvant therapy followed by liver transplantation is the only
potentially curative treatment option and should be considered
despite the prolonged treatment course and high risk for recur-
rence.
The role of liver transplantation in patients with resectable
de novo hilar CC is not well defined. As discussed, 5-year sur-
vival ranges for both margin-negative resection and neoadju-
vant therapy combined with liver transplantation are similar.
Barriers to resection include uncertainty regarding final margin
status at the time of resection and the high rate of unresecta-
bility identified at the time of operative exploration. Barriers to
liver transplantation include the significant dropout rate during
pre-transplant induction therapy and the need for longterm
immunosuppression. At this time, in light of the scarcity of
donor resources and the absence of superior results with trans-
plantation, resection should still be considered the standard of
care for patients with de novo resectable hilar CC.
In summary, the standard therapy for hilar CC is resection,
after which 5-year survival of 35–50% is possible in the setting
of R0 resection, although many patients present with unresec-
table disease. In selected patients who are not eligible for resec-
tion, neoadjuvant chemoradiation followed by liver
transplantation has facilitated excellent 5-year recurrence-free
survival.
Consensus statements
• Resection of the involved intra- and extrahepatic bile ducts
as well as the ipsilateral liver is the standard of care for suit-
able patients outside the setting of PSC.
• Portal vein embolization is a safe and effective strategy for
increasing the FLR prior to resection and may be most use-
ful in patients with an FLR of <30–40%.
• Preoperative biliary drainage in the setting of hyperbilirubi-
naemia is indicated in patients with:
○ jaundice and the need for preoperative anti-neoplastic
therapy
○ cholangitis
○ malnutrition, hepatic insufficiency or renal insufficiency
possibly related to elevated serum bilirubin
○ preparation for PVE.
• Liver transplantation following a standardized protocol
including external beam and transluminal radiation, as well
as systemic chemotherapy, is the standard of care for both
unresectable hilar CC, as well as hilar CC arising in the set-
ting of PSC.
Traditional and novel chemotherapy and
radiation approaches to hilar CC
Postoperative adjuvant therapy
The patterns of recurrence following resection of hilar CC play
an important role in defining the appropriate strategy for
adjuvant therapy. The initial site of failure following resection
is more likely to be locoregional in patients with hilar CC
(59%) than in patients with gallbladder cancer (15%).53 Based
on this pattern of tumour recurrence and retrospective studies
with limited numbers of patients, chemoradiation appears to
offer a reduction in local recurrence for patients at high risk
for recurrence. Several studies report improved overall survival
in patients treated with postoperative adjuvant chemoradiation
on multivariate analysis.54–57 In a recent non-randomized
study from Japan, Todoroki et al. reported results in 63
patients with resected perihilar cholangiocarcinoma.57 Two
thirds of patients received adjuvant radiation therapy with
either intraoperative radiation therapy, external beam therapy,
or both. The locoregional control rate was significantly better
in the adjuvant therapy group than in the resection-alone
group (80% versus 31%, respectively). The actuarial 5-year
survival was also significantly better in the resection plus radi-
ation group compared with the resection-alone group (39%
versus 14%). In a retrospective study from the MD Anderson
Cancer Center, patients with positive margins or positive
nodes were referred for postoperative chemoradiation and
showed similar locoregional recurrence rates (38% versus
37%) and overall 5-year survival (36% versus 42%) as patients
without these high-risk features who did not receive radia-
tion.58 Similar results were reported in a study from Korea
conducted in patients treated with adjuvant radiotherapy, in
which overall 5-year actuarial survival reached 31%.59 When
patients were stratified by residual tumour, 5-year survival rates
were 36% in patients with negative microscopic margins at the
time of resection, 35% in patients with positive microscopic
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margins and 0% in patients with gross residual disease. Another
study analysed patients with cholangiocarcinoma treated with
postoperative chemoradiation. The authors concluded that
chemoradiation did not improve outcome, but this older study
of intra- and extrahepatic cancers included limited numbers of
curatively resected patients treated with postoperative radiation,
and irradiated patients were significantly more likely to have
hepatic artery invasion.60,61
The first cooperative group adjuvant trial has been com-
pleted and its results are pending. Southwest Oncology Group
0809 is a single-arm, Phase II trial of postoperative chemo-
therapy followed by chemoradiation for resected cholangiocar-
cinoma and gallbladder tumours. Eighty patients were treated
with four cycles (12 weeks) of gemcitabine and capecitabine
followed by chemoradiation (54.0–59.4 Gy in 29–33 frac-
tions).
Definitive therapy for patients with locally advanced,
unresectable disease ineligible for transplant
For locally advanced inoperable tumours in patients who are
not candidates for liver transplant, definitive chemoradiation
with or without intraluminal brachytherapy has produced
modest results with median survival ranging from 10.7 months
to 14.6 months. Longterm survival has been reported after
chemoradiation followed by intraluminal brachytherapy.62 A
small (n = 42) randomized trial compared outcomes after per-
cutaneous stent placement followed by intraluminal Ir-192
brachytherapy (mean dose: 30 Gy) and external radiotherapy
(mean dose: 50 Gy) with those in patients treated with stenting
only. Patients who received radiation in addition to stenting
had longer median survival (12.9 months versus 9.9 months;
P < 0.05).63 In light of the significant morbidity and mortality
related to recurrent cholangitis, meticulous optimization of
biliary drainage is critical to improving survival rates in
incurable patients.
Definitive therapy for locally recurrent or metastatic
disease
The most common site of first failure among patients submit-
ted to resection of hilar CC is locoregional. Resection of these
recurrences should rarely be considered as local recurrence is
commonly associated with radiographically occult metastatic
disease. Definitive therapy for local recurrence using chemora-
diation is made challenging by the presence of the jejunal
reconstruction in the regional field. Radiation-related toxicity
to the jejunal limb limits the radiation approach to sites of
recurrence in this area. In addition, re-radiation following an
initial course of adjuvant chemotherapy is rarely a safe option
in patients with this disease.
There are limited prospective data with which to compare
the results of chemotherapy with those of chemoradiation in
the setting of local recurrence. The toxicity associated with
radiation to local recurrence in the area of the jejunal limb
typically precludes the use of chemoradiation or radiation
alone in this setting. The favoured approach in these patients
is systemic chemotherapy based on the rationale described
below for the treatment of patients in the metastatic setting.
The initial evidence supporting the use of gemcitabine alone
or in combination with other agents was derived from Phase II
studies (Table 1).64–71 These studies identified a cohort of trea-
ted patients in whom a treatment response to these agents was
apparent and prompted the initiation of the Advanced Biliary
Cancers (ABC)-01 trial, a Phase II study which subsequently
transitioned into the Phase III ABC-02 trial based on encour-
aging initial results.72
In 2010, the ABC-02 trial published the results of a compari-
son of gemcitabine plus cisplatin with gemcitabine alone in
patients with locally advanced or metastatic biliary tract can-
cers.73 This trial included 410 patients with intra- or extrahepatic
cholangiocarcinoma, gallbladder cancer or ampullary cancer.
Patients were randomized to either cisplatin (25 mg/m2 BSA)
Table 1 Summary of early results with gemcitabine-based systemic therapy for locally advanced or unresectable biliary tract cancers
Study (year) Trial design Tumour types Patients, n Systemic agents Response rate, %a
Kubicka et al. (2001)69 Phase II CCA 23 GEM 30%
Kuhn et al. (2002)70 Phase II CCA, GBC 43 GEM + DOC 12%
Hsu et al. (2004)66 Phase II CCA, GBC, AMP 30 GEM + 5-FU/LV 21%
Andre et al. (2004)65 Phase II CCA, GBC, AMP 56 GEMOX 36%
Tsavaris et al. (2004)71 Phase II CCA, GBC 30 GEM 30%
Kornek et al. (2004)68 RT II CCA, GBC 51 MMC + GEM versus MMC + CAPE 20% versus 31%
Knox et al. (2004)67 Retro CCA, GBC 27 GEM+5-FU 33%
Alberts et al. (2005)64 Phase II CCA, GBC, AMP 42 GEM + 5-FU/LV 10%
Valle et al. (2009)72 (ABC-01) RT II CCA, GBC, AMP 86 GEM versus GEM + CIS 23% versus 28%
aResponse rate: radiographic complete response or partial response.
5-FU, infusional 5-fluorouracil; 5-FU/LV, 5-fluorouracil followed by leucovorin; AMP, ampulla of Vater cancer; CAPE, capecitabine; CCA, cholan-
giocarcinoma; CIS, cisplatin; DOC, docetaxel; GBC, gallbladder cancer; GEM, gemcitabine; GEMOX, gemcitabine-oxaliplatin; MMC, mitomycin
C; Retro, retrospective review; RT II, randomized Phase II trial.
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followed by gemcitabine (1000 mg/m2 BSA) on days 1 and 8
every 3 weeks for eight cycles, or gemcitabine alone on days 1, 8
and 15 every 4 weeks for up to 24 weeks. Median survival in the
cisplatin–gemcitabine group was greater than that in the gemcit-
abine-alone group (11.7 months versus 8.1 months; P < 0.001).
In addition, progression-free survival and the rate of tumour
control were superior in the cisplatin–gemcitabine arm.
The French Biliary Cancers: EGFR Inhibitor, Gemcitabine and
Oxaliplatin (BINGO) trial randomized 101 patients with intra-
or extrahepatic cholangiocarcinoma, gallbladder cancer or
ampullary cancer to receive gemcitabine plus oxaliplatin with or
without cetuximab.74 This study did not demonstrate any added
benefit of the addition of an EGFR-inhibitor for these patients.
Despite the fact that the largest study of systemic chemo-
therapy for patients with advanced biliary malignancy included
a disparate collection of histologies, the ABC-02 trial provides
the best evidence for an effective chemotherapeutic strategy for
these patients. The recommended treatment modality for
patients with metastatic hilar CC is the combination of cis-
platin and gemcitabine as defined in ABC-02.
Consensus statements
• After resection of margin-positive or node-positive hilar CC,
chemoradiation should be offered to patients. The role of
adjuvant chemotherapy is still not clearly defined, but may
be considered based on clinical trial experience with
advanced biliary cancers.
• For patients with unresectable tumours who are ineligible
for liver transplantation, definitive chemoradiation with or
without intraluminal brachytherapy should be considered.
• For patients with local recurrence, chemotherapy is the rec-
ommended palliative approach because there are inherent
toxicity risks associated with radiation delivery to the jejunal
anastomosis.
• For patients with advanced and metastatic hilar CC, the stan-
dard first-line chemotherapy is gemcitabine and cisplatin.
Overall summary
Hilar cholangiocarcinoma is an uncommon gastrointestinal
malignancy which requires the collaboration of providers from
multiple disciplines including hepatobiliary surgery, transplant
surgery, medical oncology, radiation oncology, diagnostic radi-
ology, interventional radiology, gastroenterology and pathol-
ogy. This expert-level collaboration is necessary not only
because practitioners from multiple medical fields are involved
in each patient’s care, but also because the risk for disease
recurrence is high even after attempts at curative therapy. Con-
tinued efforts to standardize best practices will need to involve
all of these disciplines, as well as translational research efforts
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